We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
It is reported that the accidental genetic engineering of a single leukemic cell during the early manufacturing of CAR-T therapy tisagenlecleucel for a phase I study caused the relapse and eventual death of one patient participating in the clinical trial.
Sophiris Bio announced the conclusion of the ongoing investigation into the previously reported death of a patient in the company's Phase 2b trial for the treatment of localized prostate cancer is unlikely to be related to either topsalysin or the procedu
Ionis Pharmaceuticals announced the results from a Phase 3 trial of its drug to treat patients with familial amyloid polyneuropathy and the results were extremely positive, except for the side-effects.